Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadrivalent HPV vaccine in females aged 9-35 years
NCT06632912Phase 3Active, not recruiting
- Sponsor
- Serum Institute of India
- Start
- Nov 2025
- Primary completion
- Jul 2032
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of quadrivalent recombinant human papillomavirus vaccine in human papillomavirus infection and human papillomavirus-associated carcinoma (4 arms), sponsored by Serum Institute of India. Primary endpoint: Geometric Mean Titers of neutralizing antibodies against HPV types 6, 11, 16, and 18 (seronegative at baseline) at 7 months. Started Nov 2025; status: active, not recruiting.
02
Drugs
quadrivalent recombinant human papillomavirus vaccine
03
Conditions
human papillomavirus infectionhuman papillomavirus-associated carcinoma
Beyond the preview
Go deeper on NCT06632912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632912.